Can DAA therapy remove patients from transplant waiting lists? Are HCV-infected livers--and hearts--safe for uninfected organ recipients? Three new studies explain.
Andrew D. Bowser
Renowned transplant expert Gregory T. Everson, MD, talked with Patient Care about sensitive issues surrounding liver transplant in the era of direct-acting antiviral therapy.
Sample: Which type of practitioner most often makes the diagnosis of HCV: Gastro? GP? Hepatologist? Other?
Patient Care talked with Dr Kwo about recent updates to hepatitis C management guidelines, challenges in expanding screening, and more.
HCV screening rates improved at one large clinic from 24% to over 90% and were sustained at 1 year. How? With this 6-step intervention.
The newest HCV guidance is out on special populations. Are you up to date? Take our short, 5-question quiz to find out.
Two new international studies on HCV show elimination programs have high levels of engagement, treatment initiation, and cure rates.
For patients infected with hepatitis C virus who do not respond to direct-acting antiviral agents, results of a new study could mean a much brighter future.
These 5 questions on HCV infection are a quick brush-up on disease basics and treatment.
The current study was one of the largest analyses to date of black participants receiving all-oral DAA treatment.